aMoon Fund

Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.

Lutris Pharma is a biopharmaceutical company based in Tel Aviv-Yafo, Israel, founded in 2015. The company focuses on developing therapeutic drugs aimed at enhancing the effectiveness of anti-cancer therapies. Its lead product, LUT014, is a proprietary small molecule B-Raf inhibitor designed to facilitate the administration of epidermal growth factor receptor (EGFR) inhibitors. This innovative approach helps mitigate the common cutaneous side effects associated with EGFR treatments, thereby improving the overall quality of life for patients undergoing cancer therapy.

Lyfegen is an independent provider of drug access, pricing, and rebate management solutions, with operations in Basel, Switzerland, and Boston, USA. The company specializes in helping healthcare payers and pharmaceutical companies establish appropriate pricing agreements for medications while efficiently managing drug rebates. Its platform is designed for the healthcare industry, assisting health insurance providers, pharmaceutical companies, MedTech firms, and hospitals worldwide in collecting, analyzing, and reconciling diverse healthcare data. This technology facilitates the automation of value-based healthcare contracting, ultimately aiming to enhance access to treatments, improve patient health outcomes, and increase affordability.

MetaSight Diagnostics, a health technology company, is on a mission to develop affordable and precise liquid biopsy diagnostics for the early detection of a wide range of chronic and acute diseases by leveraging proprietary mass spectrometry technologies (metabolomics, lipidomics, and proteomics).

PrognomiQ is a technology company dedicated to advancing early disease detection and treatment, particularly for cancer and other complex diseases. By harnessing multi-omics data, including proteomic, genomic, and metabolomic information, the company aims to enhance understanding and management of health conditions. PrognomiQ's innovative approach allows for the development of advanced medical test products that improve diagnostic capabilities and recurrence monitoring, ultimately seeking to enhance patient outcomes. Through its focus on integrating diverse health data, PrognomiQ is committed to transforming how medical practitioners approach disease detection and treatment.

Air Doctor Ltd. operates an online marketplace that connects travelers with verified medical practitioners, facilitating access to healthcare services while abroad. Founded in 2016 and based in Motza Illit, Israel, the platform enables users to search for and book appointments with a variety of healthcare providers, including doctors, dentists, emergency clinics, pharmacies, and laboratories. It features profiles of practitioners along with patient reviews, allowing travelers to select professionals who meet their specific needs and speak their language. By streamlining the process of obtaining medical care in unfamiliar locations, Air Doctor enhances the travel experience for individuals seeking healthcare services.

Operator of a data-driven healthcare startup intended to transform healthcare in rural communities through exceptional care, bringing better access and quality service to its patients. The company delivers tailored quality care through a team-based model, with resources and support for patients, inside and outside clinics, thereby enabling healthcare professionals to provide the support and care that patients need.

AltruBio is a biopharmaceutical company focused on developing targeted antibody therapeutics for cancer and immune-related inflammatory diseases. Established in Delaware with its principal office in the San Francisco Bay Area, AltruBio integrates global resources to advance its research and development initiatives. The company has its roots in Taipei, Taiwan, where it has been working since June 2000 on discovering and developing novel therapeutics to address unmet medical needs. AltruBio employs a sophisticated discovery platform to identify and validate new antibody therapeutics. Currently, the company is developing several potential therapeutic antibodies that target a range of conditions, including autoimmune diseases and various types of cancer, such as pancreatic, stomach, colorectal, ovarian, and lung cancers, at different stages of development.

Eleos Health develops innovative health technology solutions aimed at enhancing decision-making for clinicians in the behavioral health sector. The company's AI-powered Speech-to-Insights system operates during mental health sessions to analyze voice data in real time. By gathering insights on patients through this voice technology, Eleos Health enables clinicians to deliver personalized, efficient, and cost-effective care. The automated nature of the system helps streamline the clinical process, ultimately supporting mental health professionals in providing the necessary care and support for their patients.

Ibex Medical Analytics Ltd, based in Tel Aviv, Israel, specializes in developing AI-based diagnostic systems for cancer pathology. The company's flagship product, the Ibex Second Read system, works alongside human pathologists to analyze cases, identifying discrepancies in diagnoses. This innovative technology harnesses artificial intelligence, data science, and machine learning to analyze digitized glass slides and electronic medical records, revealing critical patterns that enhance clinical decision-making. By streamlining pathology workflows, Ibex aims to provide rapid, objective, and accurate diagnoses, ultimately improving patient outcomes and quality of life. The company comprises a multidisciplinary team of entrepreneurs, data scientists, software engineers, and medical experts dedicated to advancing cancer care through AI applications in diagnostics.

Better Life Partners Inc. is a healthcare provider based in Hanover, New Hampshire, focused on supporting individuals struggling with opioid use disorder in the United States. Established in 2018, the company offers a range of services including medication-assisted treatment, counseling, peer coaching, and group sessions. Better Life Partners utilizes technology to create personalized care plans that adapt to clients' needs, ensuring effective healthcare delivery through telehealth and community-based solutions. By integrating medical and behavioral healthcare, the company aims to address the complex needs of patients, providing comprehensive support to help them recover from addiction. Better Life Partners has additional offices across various locations in New Hampshire, reflecting its commitment to serving vulnerable populations.

Nectin Therapeutics Ltd., founded in 2017 and based in Jerusalem, Israel, specializes in the development of monoclonal antibodies targeting members of the Nectin family of receptors and ligands. These antibodies are designed to address immune checkpoint mechanisms that play a crucial role in cancer immunotherapy. By focusing on both solid and hematological malignancies, Nectin Therapeutics aims to create therapies that can overcome the inhibitory pathways utilized by tumors, thereby enhancing the ability of immune cells to eradicate cancer cells. The company's innovative approach seeks to improve patient outcomes in cancer treatment.

Ibex Medical Analytics Ltd, based in Tel Aviv, Israel, specializes in developing AI-based diagnostic systems for cancer pathology. The company's flagship product, the Ibex Second Read system, works alongside human pathologists to analyze cases, identifying discrepancies in diagnoses. This innovative technology harnesses artificial intelligence, data science, and machine learning to analyze digitized glass slides and electronic medical records, revealing critical patterns that enhance clinical decision-making. By streamlining pathology workflows, Ibex aims to provide rapid, objective, and accurate diagnoses, ultimately improving patient outcomes and quality of life. The company comprises a multidisciplinary team of entrepreneurs, data scientists, software engineers, and medical experts dedicated to advancing cancer care through AI applications in diagnostics.

Lyfegen is an independent provider of drug access, pricing, and rebate management solutions, with operations in Basel, Switzerland, and Boston, USA. The company specializes in helping healthcare payers and pharmaceutical companies establish appropriate pricing agreements for medications while efficiently managing drug rebates. Its platform is designed for the healthcare industry, assisting health insurance providers, pharmaceutical companies, MedTech firms, and hospitals worldwide in collecting, analyzing, and reconciling diverse healthcare data. This technology facilitates the automation of value-based healthcare contracting, ultimately aiming to enhance access to treatments, improve patient health outcomes, and increase affordability.

Theranica is a medical device company that specializes in developing wearable solutions for various medical conditions, particularly focusing on migraine treatment. The company utilizes neuromodulation therapy combined with advanced wireless technology to create noninvasive 'smart' patches. These patches are controlled via a smartphone app, allowing for personalized treatment that is both portable and cost-effective. Each patch features a proprietary chip that delivers electrical pulses to modulate sensory nerves beneath the skin, providing temporary or long-term relief from pain. Theranica's innovative approach aims to empower patients in managing their neurological pain effectively and affordably.

Ultima Genomics, founded in 2016 and based in Newark, California, specializes in genome-scale sequencing technology aimed at providing analytical services to enterprises. The company employs an innovative approach using an open substrate that creates a large, low-cost reaction surface, allowing for billions of reads without the need for expensive flow cells or complex fluidics. By integrating specialized sequencing hardware with machine learning, Ultima Genomics ensures reproducible and accurate results, enabling clients to obtain genomic reports rapidly and efficiently. This technology not only enhances the scale of genomic information but also significantly reduces the costs associated with sequencing, thereby facilitating advancements in biology and improvements in human health.

Eleos Health develops innovative health technology solutions aimed at enhancing decision-making for clinicians in the behavioral health sector. The company's AI-powered Speech-to-Insights system operates during mental health sessions to analyze voice data in real time. By gathering insights on patients through this voice technology, Eleos Health enables clinicians to deliver personalized, efficient, and cost-effective care. The automated nature of the system helps streamline the clinical process, ultimately supporting mental health professionals in providing the necessary care and support for their patients.

PrognomiQ is a technology company dedicated to advancing early disease detection and treatment, particularly for cancer and other complex diseases. By harnessing multi-omics data, including proteomic, genomic, and metabolomic information, the company aims to enhance understanding and management of health conditions. PrognomiQ's innovative approach allows for the development of advanced medical test products that improve diagnostic capabilities and recurrence monitoring, ultimately seeking to enhance patient outcomes. Through its focus on integrating diverse health data, PrognomiQ is committed to transforming how medical practitioners approach disease detection and treatment.

Satellite Bio is a company that specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It is dedicated to developing a therapeutic platform aimed at creating innovative cell therapies to address complex diseases. The company’s primary focus is on the design and implementation of proprietary, off-the-shelf, implantable satellite organs, which serve as living therapeutic solutions. These satellite organs are intended to improve the lives of millions of patients suffering from serious health conditions.

MDClone Ltd. is a company that specializes in developing software for analyzing medical records while ensuring the privacy of patient data. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients, which allows researchers to study disease behavior, healthcare practices, and treatment outcomes without exposing actual patient information. The MDClone ADAMS Platform provides a self-service data analytics environment that facilitates exploration, discovery, and collaboration across healthcare systems, both nationally and internationally. This innovative approach addresses common barriers in healthcare by enabling users to organize and access data efficiently, thereby improving operations and enhancing patient outcomes. MDClone serves various clients in the healthcare sector, including major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

Omada Health, Inc. is a digital healthcare company that specializes in developing online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, California, with an additional office in Atlanta, Georgia, Omada focuses on preventing conditions such as prediabetes, diabetes, hypertension, and heart disease. The company provides personalized digital health programs that cater to the unique needs of individuals, utilizing professional health coaching, connected health devices, and real-time data to facilitate meaningful health improvements. Omada is recognized as the largest provider of the National Diabetes Prevention Program, empowering individuals to engage actively in their health and achieve sustainable lifestyle changes. The platform also addresses behavioral health issues, including anxiety and depression, further supporting individuals in their overall wellness journey.

Eleos Health develops innovative health technology solutions aimed at enhancing decision-making for clinicians in the behavioral health sector. The company's AI-powered Speech-to-Insights system operates during mental health sessions to analyze voice data in real time. By gathering insights on patients through this voice technology, Eleos Health enables clinicians to deliver personalized, efficient, and cost-effective care. The automated nature of the system helps streamline the clinical process, ultimately supporting mental health professionals in providing the necessary care and support for their patients.

MOBILion Systems, Inc. is a biotechnology company focused on advancing the detection and analysis of clinically relevant molecules that conventional instruments struggle to identify. The company has developed structures for lossless ion manipulation (SLIM), which facilitate ion mobility separations and enable researchers to detect minute traces of disease-specific biomolecules. Founded in 2015 and based in Chadds Ford, Pennsylvania, MOBILion's technology enhances the sensitivity, resolution, and throughput of analytical instruments. This innovation supports the identification of biologic therapeutics, accelerates biomarker discovery, and improves the accuracy of diagnostic tests. By processing large-scale samples efficiently, MOBILion aims to contribute to better disease prediction, diagnosis, and treatment, ultimately empowering clinicians and researchers to address diseases at their core rather than merely treating symptoms.

We're a digital healthcare company on a mission to enhance patients outcome by helping doctors and companies make better decisions through the generation of reliable synthetic data and by developing decision support systems

DayTwo Ltd. is a precision nutrition company headquartered in Tel Aviv-Yafo, Israel, that focuses on leveraging gut microbiome insights to improve health outcomes and prevent diseases such as diabetes, prediabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). Founded in 2015, DayTwo employs microbiome sequencing to create personalized dietary recommendations, known as Food Prescriptions™, tailored to individual responses to food. This approach helps manage blood sugar levels, enhance energy, control hunger, and promote weight loss. DayTwo delivers its services through a digital platform and mobile application, enabling users to track their progress and communicate with certified diabetes care specialists and registered dietitians. By emphasizing personalized nutrition based on scientific research, DayTwo aims to empower patients to lead healthier lives through informed dietary choices.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, focused on developing diagnostic tests that assess a woman's individual risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other pregnancy-related complications. Founded in 2008, Sera aims to improve maternal and neonatal health while addressing the significant economic and healthcare burdens associated with premature birth. The company's proprietary proteomics and bioinformatics platform underpins its pipeline of innovative diagnostic tests, including the PreTRM® Test, which provides physicians with critical information to identify women at higher risk for spontaneous premature delivery. By enabling earlier proactive interventions, Sera seeks to enhance pregnancy care and reduce healthcare delivery costs.

Biosplice Therapeutics is engaged in the research and development of therapeutic drugs aimed at tissue-level regeneration, with a focus on osteoarthritis and oncology. The company utilizes a platform that originated from small molecule-based modulation of the Wnt pathway, enabling the discovery of new biological targets and processes. This innovative approach allows Biosplice to develop therapeutics that address a variety of degenerative diseases, aiming to create effective treatments for conditions that currently lack adequate options. By concentrating on regenerative medicine, the company aspires to improve patient health through the advancement of new curative therapies.

AltruBio is a biopharmaceutical company focused on developing targeted antibody therapeutics for cancer and immune-related inflammatory diseases. Established in Delaware with its principal office in the San Francisco Bay Area, AltruBio integrates global resources to advance its research and development initiatives. The company has its roots in Taipei, Taiwan, where it has been working since June 2000 on discovering and developing novel therapeutics to address unmet medical needs. AltruBio employs a sophisticated discovery platform to identify and validate new antibody therapeutics. Currently, the company is developing several potential therapeutic antibodies that target a range of conditions, including autoimmune diseases and various types of cancer, such as pancreatic, stomach, colorectal, ovarian, and lung cancers, at different stages of development.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

Absci is a drug and target discovery company that leverages deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. Its Integrated Drug Creation Platform streamlines the process of identifying novel drug targets, discovering optimal biotherapeutic candidates, and generating the necessary cell lines for manufacturing. By combining biologic drug discovery and cell line development into a single, efficient workflow, Absci collaborates with biotech and pharmaceutical innovators to develop next-generation protein-based drugs. These innovations include Bionic Proteins, which feature nonstandard amino acids, and other unique drug designs that may be unattainable through conventional methods. Absci's mission is to facilitate the development of improved medicines by effectively translating innovative ideas into viable drugs.

Ibex Medical Analytics Ltd, based in Tel Aviv, Israel, specializes in developing AI-based diagnostic systems for cancer pathology. The company's flagship product, the Ibex Second Read system, works alongside human pathologists to analyze cases, identifying discrepancies in diagnoses. This innovative technology harnesses artificial intelligence, data science, and machine learning to analyze digitized glass slides and electronic medical records, revealing critical patterns that enhance clinical decision-making. By streamlining pathology workflows, Ibex aims to provide rapid, objective, and accurate diagnoses, ultimately improving patient outcomes and quality of life. The company comprises a multidisciplinary team of entrepreneurs, data scientists, software engineers, and medical experts dedicated to advancing cancer care through AI applications in diagnostics.

Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.

Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.

SOPHiA GENETICS is a healthcare technology company focused on advancing data-driven medicine and enhancing life sciences research. The company has developed the SOPHiA DDM™ Platform, a cloud-based software-as-a-service solution that analyzes complex multimodal data sets and various diagnostic modalities. This platform is utilized by over 780 hospitals, laboratories, and biopharma institutions worldwide. Headquartered in Switzerland, SOPHiA GENETICS also maintains a presence in France, the United States, and Brazil, underscoring its commitment to improving healthcare outcomes through innovative technology.

PrognomiQ is a technology company dedicated to advancing early disease detection and treatment, particularly for cancer and other complex diseases. By harnessing multi-omics data, including proteomic, genomic, and metabolomic information, the company aims to enhance understanding and management of health conditions. PrognomiQ's innovative approach allows for the development of advanced medical test products that improve diagnostic capabilities and recurrence monitoring, ultimately seeking to enhance patient outcomes. Through its focus on integrating diverse health data, PrognomiQ is committed to transforming how medical practitioners approach disease detection and treatment.

MiNA Therapeutics is a clinical-stage biotechnology company based in London, United Kingdom, focused on developing small activating RNA medicines aimed at restoring normal cell function in patients. Established in 2008, the company is advancing its pipeline with products such as MTL-CEBPA combined with Sorafenib for hepatocellular carcinoma and MTL-CEBPA in conjunction with Pembrolizumab for advanced solid tumors. MiNA's innovative approach leverages gene activation mechanisms to transform the treatment landscape for cancer and other serious diseases, enabling healthcare professionals to better address these conditions.

MOBILion Systems, Inc. is a biotechnology company focused on advancing the detection and analysis of clinically relevant molecules that conventional instruments struggle to identify. The company has developed structures for lossless ion manipulation (SLIM), which facilitate ion mobility separations and enable researchers to detect minute traces of disease-specific biomolecules. Founded in 2015 and based in Chadds Ford, Pennsylvania, MOBILion's technology enhances the sensitivity, resolution, and throughput of analytical instruments. This innovation supports the identification of biologic therapeutics, accelerates biomarker discovery, and improves the accuracy of diagnostic tests. By processing large-scale samples efficiently, MOBILion aims to contribute to better disease prediction, diagnosis, and treatment, ultimately empowering clinicians and researchers to address diseases at their core rather than merely treating symptoms.

Seer, Inc. is a life sciences company that specializes in nanoparticle technology solutions aimed at advancing proteomics research. The company offers Proteograph, an integrated system that includes consumables, automation instrumentation, and proprietary software for conducting proteomics analysis. Seer's products are designed for research applications, targeting academic institutions, life sciences laboratories, and biopharmaceutical companies for non-diagnostic and non-clinical uses. Additionally, Seer is focused on developing a health data platform that enhances early detection of chronic diseases by capturing and translating molecular insights from the proteome, thereby enabling healthcare professionals to identify conditions such as cancer and neurological disorders more accurately and rapidly. Founded in 2017 and headquartered in Redwood City, California, Seer was previously known as Seer Biosciences, Inc. before rebranding in July 2018.

Nectin Therapeutics Ltd., founded in 2017 and based in Jerusalem, Israel, specializes in the development of monoclonal antibodies targeting members of the Nectin family of receptors and ligands. These antibodies are designed to address immune checkpoint mechanisms that play a crucial role in cancer immunotherapy. By focusing on both solid and hematological malignancies, Nectin Therapeutics aims to create therapies that can overcome the inhibitory pathways utilized by tumors, thereby enhancing the ability of immune cells to eradicate cancer cells. The company's innovative approach seeks to improve patient outcomes in cancer treatment.

Curesponse is a diagnostics company based in Tel Aviv-Yafo, Israel, founded in 2017. It specializes in developing a three-dimensional tissue culture system that models cancer growth and drug response. The company's innovative platform allows patients and clinicians to send tumor samples for testing, preserving the cancer tissue's architecture, including its vasculature and immune system. This accurate reflection of cancer growth enables healthcare providers to make more informed decisions about drug therapies tailored to individual patients. By moving beyond traditional genomic predictions to functional responses in living patient cells, Curesponse aims to enhance personalized cancer medicine, improve survival rates, and reduce unnecessary medical interventions.

AtaCor Medical, Inc. is a medical device company based in San Clemente, California, focused on cardiac pacing and rhythm management. Founded in 2014, the company has developed the AtaCor EV Temporary Pacing System, an innovative implantable system that utilizes a parasternal approach to provide temporary pacing without the need for traditional leads or hardware attached to the heart. This system introduces a pacing lead into the extracardiac tissue located between the ribs and pericardium, allowing for quick and effective restoration of cardiac rhythm in patients. AtaCor Medical aims to enhance the delivery of temporary, interim, and permanent cardiac pacing solutions in critical situations.

AposHealth is dedicated to transforming the treatment of musculoskeletal conditions by focusing on gait analysis to alleviate pain and enhance mobility. Its primary product, Apos®, is an FDA-cleared device designed to temporarily reduce knee pain associated with osteoarthritis and also serves as a wellness tool for managing chronic lower back and hip pain. The Apos system includes a personalized foot-worn device, comprehensive gait analysis, and a tailored treatment plan, which collectively aim to improve patient outcomes. With a 96 percent satisfaction rate and over 110,000 patients treated, AposHealth supports its effectiveness with numerous peer-reviewed studies. The company's approach emphasizes a drug-free and non-surgical method, allowing patients to better manage their discomfort and promote a healthier lifestyle.

Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, that focuses on developing innovative CRISPR solutions for a variety of applications. The company offers DETECTR™, a diagnostic platform that identifies specific nucleic acids in samples, aiding in the detection of diseases such as bacterial infections, cancer, and viral infections. Additionally, Mammoth Biosciences provides CRISPR-Cas systems for genome editing, targeting therapeutic areas including immuno-oncology, autoimmune diseases, and liver diseases. By harnessing proprietary ultracompact proteins and leveraging advanced research and development, Mammoth aims to create affordable point-of-care tests and enhance diagnostics across healthcare, agriculture, and environmental monitoring. Co-founded by CRISPR pioneer Jennifer Doudna, the company has attracted significant investment from institutional and individual backers.

NanoGhost is a company focused on developing innovative drug-delivery technology aimed at treating the most aggressive forms of cancer. Founded on research from the Technion, which has been patented in the U.S. and Europe, the company's approach utilizes adult stem cells to transport medication directly to tumor sites. This targeted delivery system is designed to shrink tumors associated with small lung carcinoma, prostate cancer, and pancreatic cancer, thereby alleviating the pain and discomfort often experienced during radiation treatments. Through its advanced technology, NanoGhost seeks to improve the quality of life for cancer patients by enhancing the efficacy of treatment while minimizing side effects.

Seer, Inc. is a life sciences company that specializes in nanoparticle technology solutions aimed at advancing proteomics research. The company offers Proteograph, an integrated system that includes consumables, automation instrumentation, and proprietary software for conducting proteomics analysis. Seer's products are designed for research applications, targeting academic institutions, life sciences laboratories, and biopharmaceutical companies for non-diagnostic and non-clinical uses. Additionally, Seer is focused on developing a health data platform that enhances early detection of chronic diseases by capturing and translating molecular insights from the proteome, thereby enabling healthcare professionals to identify conditions such as cancer and neurological disorders more accurately and rapidly. Founded in 2017 and headquartered in Redwood City, California, Seer was previously known as Seer Biosciences, Inc. before rebranding in July 2018.

Vocalis Health is a health technology company founded in 2019 and based in Tel Aviv, Israel, with an additional office in the United States. The company specializes in developing an artificial intelligence platform that utilizes vocal biomarkers to monitor and diagnose health conditions through voice analysis. Its technology enables healthcare providers to remotely screen and monitor patients affected by various voice-related diseases, including chronic respiratory and cardiac conditions, as well as mental health issues like depression. By employing machine learning and deep learning techniques, Vocalis Health's platform analyzes the acoustic features of voice recordings, providing valuable insights that help assess the severity and presence of health conditions, all accessible via a mobile application or web browser. The company was formed through the merger of Beyond Verbal and Healthymize.

Igentify Ltd is a company focused on preventive healthcare through genomic products and services, with a particular emphasis on the Jewish and Israeli population. Founded in 2016 and headquartered in Haifa, Israel, Igentify developed FamilyFirst, an expanded carrier screening tool designed to identify genetic conditions. The company operates an end-to-end digital genetic platform that enhances the accessibility and usability of genomic information for clinicians, laboratories, and patients. By streamlining processes such as education on genetic testing, consent collection, and data analysis, Igentify aims to facilitate a more efficient and comprehensive approach to genomic medicine.

MDClone Ltd. is a company that specializes in developing software for analyzing medical records while ensuring the privacy of patient data. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients, which allows researchers to study disease behavior, healthcare practices, and treatment outcomes without exposing actual patient information. The MDClone ADAMS Platform provides a self-service data analytics environment that facilitates exploration, discovery, and collaboration across healthcare systems, both nationally and internationally. This innovative approach addresses common barriers in healthcare by enabling users to organize and access data efficiently, thereby improving operations and enhancing patient outcomes. MDClone serves various clients in the healthcare sector, including major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

DayTwo Ltd. is a precision nutrition company headquartered in Tel Aviv-Yafo, Israel, that focuses on leveraging gut microbiome insights to improve health outcomes and prevent diseases such as diabetes, prediabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). Founded in 2015, DayTwo employs microbiome sequencing to create personalized dietary recommendations, known as Food Prescriptions™, tailored to individual responses to food. This approach helps manage blood sugar levels, enhance energy, control hunger, and promote weight loss. DayTwo delivers its services through a digital platform and mobile application, enabling users to track their progress and communicate with certified diabetes care specialists and registered dietitians. By emphasizing personalized nutrition based on scientific research, DayTwo aims to empower patients to lead healthier lives through informed dietary choices.

Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company based in Rehovot, Israel, founded in 2017. The company specializes in developing small molecule therapeutics for rare and aggressive cancers, focusing on genetically defined patient populations. Its lead product candidate is AL101, an intravenous gamma secretase inhibitor currently in Phase II clinical trials for treating recurrent/metastatic adenoid cystic carcinoma in patients with Notch-activating mutations. Additionally, Ayala Pharmaceuticals is developing AL102, an oral gamma secretase inhibitor in Phase I clinical trials for desmoid tumors. The company has a collaboration agreement with Novartis to develop AL102 for multiple myeloma. Ayala's approach involves using bioinformatics and next-generation sequencing to identify and address tumorigenic drivers of cancer, aiming to deliver targeted therapies to underserved patient populations.

Ibex Medical Analytics Ltd, based in Tel Aviv, Israel, specializes in developing AI-based diagnostic systems for cancer pathology. The company's flagship product, the Ibex Second Read system, works alongside human pathologists to analyze cases, identifying discrepancies in diagnoses. This innovative technology harnesses artificial intelligence, data science, and machine learning to analyze digitized glass slides and electronic medical records, revealing critical patterns that enhance clinical decision-making. By streamlining pathology workflows, Ibex aims to provide rapid, objective, and accurate diagnoses, ultimately improving patient outcomes and quality of life. The company comprises a multidisciplinary team of entrepreneurs, data scientists, software engineers, and medical experts dedicated to advancing cancer care through AI applications in diagnostics.

Theranica is a medical device company that specializes in developing wearable solutions for various medical conditions, particularly focusing on migraine treatment. The company utilizes neuromodulation therapy combined with advanced wireless technology to create noninvasive 'smart' patches. These patches are controlled via a smartphone app, allowing for personalized treatment that is both portable and cost-effective. Each patch features a proprietary chip that delivers electrical pulses to modulate sensory nerves beneath the skin, providing temporary or long-term relief from pain. Theranica's innovative approach aims to empower patients in managing their neurological pain effectively and affordably.

AtaCor Medical, Inc. is a medical device company based in San Clemente, California, focused on cardiac pacing and rhythm management. Founded in 2014, the company has developed the AtaCor EV Temporary Pacing System, an innovative implantable system that utilizes a parasternal approach to provide temporary pacing without the need for traditional leads or hardware attached to the heart. This system introduces a pacing lead into the extracardiac tissue located between the ribs and pericardium, allowing for quick and effective restoration of cardiac rhythm in patients. AtaCor Medical aims to enhance the delivery of temporary, interim, and permanent cardiac pacing solutions in critical situations.

Nobio Ltd. is an Israel-based company that specializes in developing innovative nano-polymer additives designed to protect against microbial infections. Their technology offers a unique, fully-integrated anti-biofilm solution, utilizing potent particles embedded in various materials and products to inhibit biofilm formation indefinitely. Nobio's product line includes a universal bonding agent that provides strong adhesion for dental applications, as well as flowable composites suitable for various restorative procedures. By transforming both implantable and non-implantable devices into biofilm-resistant platforms, Nobio aims to enhance the safety and durability of medical and dental materials through its advanced antimicrobial technology.

Zebra Medical Vision Ltd. is a company that develops an imaging analytics platform aimed at enhancing patient care in healthcare institutions. Founded in 2014 and based in Shefayim, Israel, the platform utilizes advanced learning and computer vision algorithms to assist clinicians in identifying patients at risk of various diseases. This technology supports healthcare providers in implementing effective risk management and preventative care strategies. Zebra Medical Vision also supplies tools and datasets for machine-learning researchers, facilitating the rapid development of decision support tools and diagnostic solutions. The company has established strategic partnerships with organizations such as USARAD Holdings and TELUS Ventures, and has secured a total of $52 million in funding from notable investors, including Khosla Ventures and Nvidia. Its AI-driven products are FDA cleared and are utilized in hospitals across multiple regions, including the U.S., Europe, Australia, India, and Latin America, positioning Zebra Medical Vision as a leader in the field of medical imaging and analytics.

Medial EarlySign Ltd is a healthcare technology company based in Kfar Malal, Israel, founded in 2009. The company specializes in developing AI-driven platforms designed to enhance clinical decision-making and disease management. Its primary offerings include AlgoMarkers and AlgoAnalyzer, predictive engines that utilize basic medical information, such as blood test results and electronic medical records, to identify risks associated with critical health threats. By analyzing extensive datasets from millions of patient records, Medial EarlySign aims to deliver actionable clinical insights that enable healthcare providers to predict outcomes related to cancers, metabolic, immune, and infectious diseases. These tools empower organizations to optimize care for individuals, facilitate proactive health management, and potentially reduce healthcare costs by improving patient outcomes and resource allocation.

Karius, Inc. is a life sciences company based in Redwood City, California, specializing in genomic insights for infectious diseases. The company offers a non-invasive blood test known as the Karius Test, which utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. By mapping the microbial landscape of each patient from a single blood draw, Karius aims to assist clinicians in making rapid and informed treatment decisions. The company's laboratory is CLIA-certified and CAP-accredited, ensuring high standards in clinical laboratory testing. Additionally, Karius provides laboratory services for pathogen biomarker detection tailored to biopharmaceutical companies.

CartiHeal is a medical device company based in Kfar Sava, Israel, specializing in cartilage and bone regeneration. Founded in 2009, the company has developed the Agili-C implant, a cell-free and off-the-shelf solution designed to address focal articular cartilage and osteochondral defects. This innovative implant promotes the regeneration of hyaline cartilage and the underlying subchondral bone without the need for cells or growth factors, making it a significant advancement in the treatment of cartilage injuries. Given the limited natural healing capacity of hyaline cartilage, CartiHeal's technology offers a promising option for patients suffering from cartilage damage, which can lead to severe pain and disability if untreated. The Agili-C implant can be inserted using arthroscopic or minimally invasive techniques, facilitating faster rehabilitation and enhanced recovery outcomes for patients.